FDA.reportPublic FDA data

Uptravi 0.6 MG Oral Tablet

RxCUI
1729061
RxNorm name
Uptravi 0.6 MG Oral Tablet
Display name
Uptravi 0.6 MG Oral Tablet
Full name
Uptravi 0.6 MG Oral Tablet
Term type
SY
Status
DailyMed mapping
Updated
2026-06-04 23:39:13

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
UPTRAVISELEXIPAGActelion Pharmaceuticals US, Inc.a7a23b87-f892-4e2c-8e2e-ebf841220f902026-05-28Warnings, Adverse reactionsExact identifier
rxcui: 1729061

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 1 matching rows.

Set ID, RxNorm mappings, Terms table
Set IDRxNorm mappingsTermsSPL versionLabelEffective
a7a23b87-f892-4e2c-8e2e-ebf841220f90Uptravi 600 MCG Oral Tablet [PSN] · selexipag 0.6 MG Oral Tablet [Uptravi] [SBD] · Uptravi 0.6 MG Oral Tablet [SY] · Uptravi 600 MCG Oral Tablet [SY]426These highlights do not include all the information needed to use UPTRAVI safely and effectively. See full prescribing information for UPTRAVI. UPTRAVI ® (selexipag) tablets, for oral use UPTRAVI ® (selexipag) for injection, for intravenous use Initial U.S. Approval: 201520260528